clinical trial · NCT07673900
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc.·phase1·recruiting·n = 62
Overweight and/or ObesityVX-201semaglutide SC
brief summary
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
started
Jun 15, 2026
primary completion
Feb 10, 2027
completion
May 18, 2027
last updated
Jul 31, 2026
official title
A Randomized, Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Epi/Intra-dermally Administered Semaglutide (VX-201) Compared to Subcutaneous Administration in Healthy Overweight and Obese Participants: Single and Multiple Dose Assessment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol